Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Wegener Granulomatosis Clear all
Not listed Phase 3 Interventional

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

NCT01933724
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
Interventions
5 mg prednisone, 0 mg prednisone
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

NCT00001541
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Nov 3, 2026, 4:34 PM EST
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 2Phase 3 Interventional

Etanercept for Wegener's Granulomatosis

NCT00005007
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
11 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Nov 3, 2026, 4:34 PM EST
Terminated No phase listed Observational

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

NCT01586858
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Observational
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational

The ANCA Vasculitis Questionnaire (AAV-PRO©)

NCT02507024
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (Wegener's) (GPA), Wegener Granulomatosis (WG), Microscopic Polyangiitis (MPA), ANCA-Associated Vasculitis (AAV), Vasculitis
Interventions
Online questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Nov 3, 2026, 4:34 PM EST
Recruiting No phase listed Observational

One-Time DNA Study for Vasculitis

NCT01241305
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography

NCT00001759
View directory record Official record
Conditions
Asthma, Hypersensitivity, Lung Diseases, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational

Vasculitis Illness Perception (VIP) Study

NCT02190916
View directory record Official record
Conditions
Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Nov 3, 2026, 4:34 PM EST
Recruiting Phase 3 Interventional

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 2Phase 3 Interventional Results available

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

NCT00104299
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions
Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 2 Interventional

Steroids and Methotrexate to Treat Systemic Vasculitis

NCT00001256
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
prednisone and methotrexate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 3 Interventional Results available

Rituximab Vasculitis Maintenance Study

NCT01697267
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Interventions
Rituximab, Azathioprine
Biological · Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
15 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational Results available

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 3, 2026, 4:34 PM EST
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 3, 2026, 4:34 PM EST
Not listed No phase listed Observational

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

NCT01066208
View directory record Official record
Conditions
Wegener's Granulomatosis, Microscopic Polyangiitis, Churg Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu Arteritis
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years and older
Enrollment
3,588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Nov 3, 2026, 4:34 PM EST
Completed No phase listed Observational

Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides

NCT00001473
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:34 PM EST
Recruiting Phase 1 Interventional

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562
View directory record Official record
Conditions
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Interventions
AB-101, Rituximab, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Nov 3, 2026, 4:34 PM EST
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 4:34 PM EST
Recruiting No phase listed Observational

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

NCT00315380
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2028
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 3, 2026, 4:34 PM EST
Completed Phase 2 Interventional Results available

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
6
States / cities
Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 3, 2026, 4:34 PM EST